The world of genetics is fascinating and there always seems an endless stream of findings and breakthroughs with the potential for predicting and treating health problems.
This month, research published in the New England Journal of Medicine indicated women with mutations in the PALB2 gene face a one in three chance of getting breast cancer by age 70.
A team at the Institute of Cancer Research, in London, have shown 14 separate genetic mutations can greatly increase the odds of aggressive prostate cancers and form the basis for genetic screening in a similar way to breast cancer in women.
Scientists are even looking at DNA and its links to eating disorders to predict who might be at risk.
This voracious programme of research is ongoing and it’s an arena where chemical engineers are active too.
Armed with the knowledge that cancer can be caused by genetic mutations, and more recently the discovery that chemical modifications of a gene can also contribute to cancer, chemical engineers at Massachusetts Institute of Technology (MIT) are taking a closer look at these alterations – known as epigenetic modifications – which control whether a gene is turned on or off.
Analyzing these modifications can provide important clues to the type of tumor a patient has, and how it will respond to different drugs. For example, patients with glioblastoma, a type of brain tumour, respond well to a certain class of drugs known as alkylating agents if the DNA-repair gene MGMT is silenced by epigenetic modification.
The team of MIT chemical engineers has now developed a fast, reliable method to detect this type of modification, known as methylation, which could offer a new way to choose the best treatment for individual patients.
Hadley Sikes, the Joseph R. Mares assistant professor of chemical engineering at MIT said: “It’s pretty difficult to analyze these modifications, which is a need that we’re working on addressing. We’re trying to make this analysis easier and cheaper, particularly in patient samples.
MIT explains that in some cancers, the MGMT gene is turned off when methyl groups attach to specific locations in the DNA sequence. When this happens, proteins bind the methylated bases and effectively silence the gene by blocking it from being copied into RNA. This very small chemical modification triggers a sequence of events where that gene is no longer expressed.
Current methods for detecting cytosine methylation work well for large-scale research studies, but are hard to adapt to patient samples.
Most techniques require a chemical step called bisulfite conversion; the DNA sample is exposed to bisulfite, which converts unmethylated cytosine to a different base. Sequencing the DNA reveals whether any methylated cytosine was present.
However, this method doesn’t work well with patient samples because you need to know precisely how much methylated DNA is in a sample to calculate how long to expose it to bisulfite.
Hadley explains: “When you have limited amounts of samples that are less well defined, it’s a lot harder to run the reaction for the right amount of time. You want to get all of the unmethylated cytosine groups converted, but you can’t run it too long, because then your DNA gets degraded”.
MIT’s new approach avoids bisulfite conversion completely. Instead, it relies on a protein called a methyl binding domain (MBD) protein, which is part of cells’ natural machinery for controlling DNA transcription. This protein recognizes methylated DNA and binds to it, helping a cell to determine if the DNA should be transcribed.
The other key component of the system is a biochip — a glass slide coated with hundreds of DNA probes that are complementary to sequences from the gene being studied.
When a DNA sample is exposed to this chip, any strands that match the target sequences are trapped on the biochip. The researchers then treat the slide with the MBD protein probe. If the probe binds to a trapped DNA molecule, it means that sequence is methylated.
The binding between the DNA and the MBD protein can be detected either by linking the protein to a fluorescent dye or designing it to carry a photosensitive molecule that forms hydrogels when exposed to light.
The MIT team is now adapting the device to detect methylation of other cancer-linked genes by changing the DNA sequences of the biochip probes. They also hope to create better versions of the MBD protein and to engineer the device to require less DNA.
With the current version, doctors would need to do a surgical biopsy to get enough tissue, but the researchers would like to modify it so the test could be done with just a needle biopsy.
As a professor of energy engineering, I don’t always have the opportunity to take a look and appreciate the work of chemical engineers in other fields. However, this story has certainly caught my eye and great example of why Chemical Engineering Matters in so many ways.
One thought on “It’s in our genes (Day 85)”
Since the human body is basically a complex chemical reactor, chemical engineers has a role to play in understanding how it works and creating models to allow better treatments to be developed.
In my view this will be one of next great areas of chemical engineering.